Program
fropenem
Also written as “Faropenem”, “Faropenem(high dose group)” and “Faropenem(low-dose group)”.
Its studies are mostly in Community-Acquired Pneumonia, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 20 open or running | phase 3since Sep 4, 2013 | Jun 14, 2013 | none ahead |
| Dr. Md. Alimur Reza | 10 open or running | phase 4since Jan 26, 2025 | Jan 26, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 14, 2013First study: phase 2 study in Community-Acquired PneumoniaNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT01886053 · 189 enrolled · China
- Sep 4, 2013Phase 3 study in Community-Acquired PneumoniaSino Biopharmaceutical · NCT01937832 · 540 enrolled · China
- Jan 26, 2025Dr. Md. Alimur Reza's first study: phase 4 study in Community-Acquired PneumoniaNew to Dr. Md. Alimur RezaDr. Md. Alimur Reza · NCT06804096 · 129 enrolled · Bangladesh
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Bacterial penicillin-binding protein inhibitor”ChEMBL 37, by rule
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06804096Community-Acquired Pneumonia · Bangladesh | 4 | Completed | Dr. Md. Alimur Reza | Jan 12, 2026 | 129 |
| NCT01937832Community-Acquired Pneumonia · China | 3 | UNKNOWN | Sino Biopharmaceutical | Oct 2015 | 540 |
| NCT01886053Community-Acquired Pneumonia · China | 2 | Completed | Sino Biopharmaceutical | Jul 2012 | 189 |
How it is read
Names in the registry
- “Faropenem”, 2 entries
- “Faropenem(high dose group)”, 1 entry
- “Faropenem(low-dose group)”, 1 entry
Conditions, from the studies’ own filings
- Community-Acquired Pneumonia, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.